Centessa Pharmaceuticals — Investor Presentation (June 2022)
41 slides from Centessa Pharmaceuticals's investor presentation, Jun 2, 2022
Slide 1: Corporate Overview June 2022
Corporate Overview JUNE 2022
Slide 2: Disclaimer and forward-looking statements
This presentation has been prepared by Centessa Pharmaceuticals plc (the “Company”) for informational purposes only and not for any other purpose. This presentation does not contain all the information that is or may be material to investors or potential investors and should not be considered as adv
Slide 3: R&D innovation engine to deliver impactful medicines to patients
3 We are an R&D innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients
Slide 4: Centessa management team with deep R&D experience
Centessa management team with deep R&D experience 4 MARELLA THORELL Chief Accounting Officer THOMAS TEMPLEMAN PhD Chief Technology Officer DAVID CHAO PhD Chief Administrative Officer TIA BUSH Chief Quality Officer SAURABH SAHA MD PhD Chief Executive Officer ANTOINE YVER MD MSc EVP & Chairman of Deve
Slide 5: Portfolio of rare disease and immuno-oncology programs
5 Portfolio of rare disease and immuno- oncology programs targeting multi-billion dollar markets SerpinPC in Hemophilia (Hemophilia B for initial registrational trial) REGISTRATIONAL (Programs in registrational trials this year) LB101 and LB201 in Solid Tumors ZF874 in Alpha-1 Antitrypsin Deficiency
Slide 6: Asset, disease, reason to believe, market validation
Asset Disease Reason to believe Market validation SerpinPC Hemophilia A and B Associated with promising ABR reduction and infrequent subcutaneous dosing with limited risk of thrombosis $2B+ licensing deal in 2020 for Hemophilia B gene therapy in Phase 3 clinical trials LB101 / LB201 Solid Tumors Pla
Slide 7: Upcoming 2022 catalysts with cash runway into 2026
Upcoming 2022 catalysts with cash runway now into 2026 $544.5 million cash and cash equivalents as of March 31, 2022 Note: On June 2, 2022, the Company updated its cash runway estimate following its strategic decision to voluntarily discontinue development of lixivaptan. Cash runway does not include
Slide 8: SerpinPC in Hemophilia
SerpinPC in Hemophilia 8
Slide 9: SerpinPC potential to shift Hemophilia B treatment paradigm
SerpinPC has the potential to shift Hemophilia B treatment paradigm 9 • Human genetic target validation in individuals who co-inherit Factor V Leiden mutation and either FVIII or FIX mutations reinforced with positive proof-of-concept Phase 2 data GENETIC VALIDATION AND CLINICAL PROOF OF CONCEPT FOR
Slide 10: SerpinPC unique MoA supported by human genetics
SerpinPC is believed to have a unique MoA supported by human genetics 10 Extrinsic Tenase Intrinsic Tenase Prothrombinase Prothrombin Thrombin SerpinPC APC Protein C Feedback Loop SerpinPC reduces levels of circulating APC (1), thereby prolonging activity of prothrombinase (2) and directly increasin
Slide 11: SerpinPC reductions in bleeding rates in Phase 2a
SerpinPC showed promising reductions in bleeding rates and was observed to be well-tolerated in the Phase 2a study Across all dose levels: • No thrombosis • No instances of sustained elevations in D-dimer • 1 moderate skin reaction led to withdrawal of a subject with history of a skin disorder • Two
Slide 12: Two registrational trials planned in Hemophilia B
Two registrational trials planned to start in 2H 2022 in Hemophilia B Hem B without inhibitors Part 1 Randomized dose-justification (24 weeks on treatment, n = 60) Observation period SerpinPC Multiple cohorts with different dosing frequency Hem B without inhibitors Part 2 Expansion phase at selected
Slide 13: LB101 & LB201 in Solid Tumors
13 LB101 & LB201 in Solid Tumors
Slide 14: LockBody platform to redefine tumor-specific cell killing
LockBody® platform aims to redefine tumor-specific cell killing 14 • LockBody® mechanism aims to bypass “sink” effects, minimize peripheral toxicity, and enable tumor- localized effector function activity of contingent domains, such as CD47 or CD3, directly into the tumor PLATFORM DESIGNED TO ADDRES
Slide 15: Unique, modular platform for multiple LockBody permutations
15 Confidential Unique, modular platform for multiple LockBody® permutations Constitutive Fab options for targets expressed in diseased tissues Hinge options with tunable rates of cleavage Contingent Fab options for tumor cell or immune cell engager targets Fc region variations for further modulatio
Slide 16: LB101 provides anti-PD-L1 plus CD47-targeted activity in the TME
16 Constitutive Fabs: PD-L1 Domains Fully human Contingent Fabs: Locked CD47 Domains Natural cleavage of IgG-derived hinges in tumors IgG1 Fc Exposed CDRs Locked Unlocked LB101 is designed to provide anti-PD-L1 activity plus CD47-targeted activity in the TME
Slide 17: LockBody mechanism uses IgG-derived hinges susceptible to proteases
LockBody® mechanism uses human IgG-derived hinges susceptible to multiple proteases in the TME 17 Jordan et al. “Proteinase-nicked IgGs: an unanticipated target for tumor immunotherapy” Oncoimmunology 2018 -D-K-T-H-T-C-P-P-C-P-A-P-E-L-L-G-G- Plasmin HNE Papain MMP-3, MMP-12 GluV8, Cathepsin G Pepsin
Slide 18: In vitro: LB101 target binding in locked and unlocked states
In vitro: LB101 demonstrated expected target binding in locked and unlocked states 18 LB101 binding to PD-L1 in the locked form, with CD47 binding after activation in the unlocked form Anti-PD-L1 potency similar to atezolizumab in locked form, and strongly enhanced ADCP in unlocked form Unlocked: CD
Slide 19: In vivo: LB101 improved efficacy and durability
In vivo: LB101 showed improved efficacy and durability over control and atezolizumab in a difficult-to-treat mouse model and was well tolerated Single-agent LB101 delivered systemically resulted in PD-L1 directed, local tumor-specific CD47 effector engagement leading to significant tumor regressions
Slide 20: In vivo: systemic LB101 significant tumor regression
In vivo: Systemically delivered LB101 exhibited significant tumor regression 20 Note: Arrows indicate dosing every 3 days (Q3d x 6) at Days 0, 3, 6, 9, 12, and 15. 5 mg/kg of atezolizumab is equivalent to 8.5 mg/kg of LB101. 3000 2000 1000 0 0 Study Day IgG1 isotype control Atezolizumab 5 mg/kg Atez
Slide 21: In vivo: LB101 higher survival, no growth in rechallenge
In vivo: LB101 led to higher survival and showed no tumor growth in rechallenge experiment 21 Note: Arrows indicate dosing every 3 days (Q3d x 6) at Days 0, 3, 6, 9, 12, and 15. 5 mg/kg of atezolizumab is equivalent to 8.5 mg/kg of LB101. Higher survival in mice treated with LB101 compared to isotyp
Slide 22: In vivo: LB101 well tolerated with no weight loss
In vivo: LB101 was well tolerated with no weight loss 22 40.0 35.0 30.0 25.0 15.0 10.0 5.0 0.0 0 Study Days IgG1 Isotype, 10mg/kg, 10 μl/g, i.p. Atezolizumab, 5mg/kg, 10 μl/g, i.p. Atezolizumab, 10mg/kg, 10 μl/g, i.p. LB101, 8.5mg/kg, 10 μl/g, i.p. LB101, 17 mg/kg, 10 μL/g, i.p. 10 20 40 50 M e a n
Slide 23: LockBody development plan and upcoming milestones
LockBody® development plan and upcoming milestones 23 Planning to submit an IND for LB101 (PD-L1xCD47 LockBody®) in late 2022 Planning to submit an IND for LB201 (PD-L1xCD3 LockBody®) in 2023 Continuing to explore full potential of the technology in improving the therapeutic index of other anticance
Slide 24: ZF874 in AATD
ZF874 in AATD 24
Slide 25: ZF874 potential disease-modifying treatment for AATD
ZF874 has the potential to be a disease-modifying treatment for AATD 25 • ZF874 is designed to bind to the stalled folding intermediate specific to Z-A1AT with no detectable binding to fully folded Z-A1AT in vitro; ZF887 in preclin. development, structurally unrelated to ZF874 DESIGNED AS A CATALYTI
Slide 26: Low doses of ZF874 clear polymer and reduce fibrosis
26 ZF874-treated 54 mpk/day (HED 7 mpk/day) Vehicle Z-A1AT polymer (PAS-D staining) Fibrosis (Sirius Red staining) Liver histology from 84-day treatment of mice expressing human Z-A1AT (PiZ mice) Abbreviations: mpk = milligrams per kilogram; PAS-D = Periodic Acid-Schiff staining with diastase; HED =
Slide 27: Clinical data in PiMZ subjects dosed with placebo or ZF874
Clinical data in PiMZ subjects dosed with placebo or ZF874 15 mpk BID 27 * Activity level equivalent to molar amount of M A1AT reference standard. Baseline for each subject = average of Pre-Screen , Day -1, and Day 1 Pre-Dose values for each subject † Trapezoidal AUC for the first 12 hours after the
Slide 28: Liver signal in one PiMZ subject with highest exposure
Liver signal in one PiMZ subject with highest exposure in Part B 0 100 200 300 400 500 600 700 -21 -14 -7 0 7 14 21 28 35 42 49 56 63 70 28 ALT (IU/L) Time after 1st dose (days) Treatment period ULN ♂ (70 IU/L) Subject 2002 ♂ Placebo Subject 2003 ♀ AUC0-12hr 181 µg·hr/ml Subject 2001 ♂ AUC0-12hr 350
Slide 29: Overview of ongoing Phase 1 trial of ZF874 in AATD
Overview of ongoing Phase 1 trial of ZF874 in AATD 1. Morning doses given in the fasted state. Evening doses given after an evening meal Note: 2 subjects received placebo in each cohort for Cohorts 1-6 and none in Cohort 7 15 mg/kg, fed Part A, Cohort 7 (n=6)25 mg/kg BID(1) Part A, Cohort 6 (n=8) 15
Slide 30: MGX292 in PAH
MGX292 in PAH 30
Slide 31: MGX292 potential for disease reversal in PAH
MGX292 has the potential for disease reversal / modification in PAH 31 • Recombinant modified BMP9 replacement protein designed to directly target BMPR2/ALK1 pathway vs. experimental therapies which inhibit Activin signaling with only indirect effects on this pathway DESIGNED TO DIRECTLY TARGET CENT
Slide 32: MGX292 directly targets central underlying disease mechanism
MGX292 is designed to directly target central underlying disease mechanism 32 In PAH, reduced BMP9 signaling results in the pathological changes underlying PAH. With MGX292 treatment, supplementation with exogenous recombinant BMP9 protein (MGX292) leads to restored signaling and normalization of en
Slide 33: MGX292 dose-dependent reversal of lung vascular pathology
MGX292 demonstrated dose-dependent reversal of established lung vascular pathology in Sugen-hypoxia rat model MGX2921 reversed neointimal lesions in Sugen-hypoxia rat model of severe PAH 0 5 10 15 20 Normoxic vehicle 3 weeks vehicle 7 weeks vehicle BMP9 (10µg/kg) MGX292 (3µg/kg) MGX292 (10µg/kg) MGX
Slide 34: Development plan for MGX292 in PAH
Development plan for MGX292 in PAH Preclinical development ongoing, currently in the IND-enabling stage Plan to conduct pre-IND meeting with the FDA in the second half of 2022 Plan to submit an IND for MGX292 in early 2023 34
Slide 35: OX2R Agonists in NT1
35 OX2R Agonists in NT1
Slide 36: Orexin agonists potential to change standard of care in narcolepsy
Our novel orexin agonist approaches have the potential to change the global standard of care in narcolepsy 36 • Lead molecules are designed to selectively target the Orexin Receptor-2 (OX2R) based on structure- based drug design DESIGNED TO DIRECTLY TARGET UNDERLYING PATHOPHYSIOLOGY OF DISEASE • Obs
Slide 37: Small molecule and peptide orexin agonists replacement therapy
Our small molecule and peptide orexin agonists are designed to provide a potential replacement therapy approach in NT1 37 Example X-ray structure of OX2R with small molecule orexin agonist (shown in purple) Example Cryo-EM structure of OX2R with peptide agonist (shown in purple) Our small molecule a
Slide 38: Orexin agonists increase wakefulness in mice
Novel small molecule and peptide orexin agonists demonstrated dose- dependent effects in increasing wakefulness in mice Exemplar small molecule agonists Exemplar peptide agonist Wakefulness detected by piezoelectric monitoring, which is a rapid, non-invasive method for classifying sleep and wakefuln
Slide 39: Development plan for orexin agonists in NT1
Development plan for orexin agonists in NT1 Plan to submit IND / CTA for lead oral program in 2023 Plan to submit IND / CTA for intranasal program in 2023 Intend to explore additional indications beyond NT1 39
Slide 40: Key value drivers
Key value drivers 40 Note: Cash runway does not include the remaining available tranches under the Oberland facility Substantial innovative pipeline of rare disease and immuno -oncology assets targeting multi-billion dollar markets Potential for multiple clinical proof of concept (PoC) readouts over
Slide 41: Centessa Pharmaceuticals
x CENTESSA PHARMACEUTICALS
Centessa Pharmaceuticals — Investor Presentation (June 2022) on 6ix